United Therapeutics (UTHR) Q2 2025 Earnings Call July 30, 2025 09:00 AM ET Speaker0Good morning, and welcome to the United Therapeutics Corporation Second Quarter twenty twenty five Corporate Update. My name is Steve, and I'll be your conference operator today. All participants on the call portion of the webcast will be in a listen only mode until the question and answer portion of this earnings call. Please note this call is being recorded. I would now like to turn the webcast over to Dhiv Steedman, Head o ...

ASP Isotopes Inc. Series Seed Investment in IsoBio, Inc. July 2025 In order to help you to better understand the medical isotopes business of ASP Isotopes Inc. - where we have been and where we want to go – and the business of IsoBio, Inc. (which today is a nascent business but we believe has great potential), my remarks today (and the remarks of other officers of ASP Isotopes Inc. and others who will speak or respond to questions) will include forward-looking statements relating to anticipated financial pe ...

Wave Life Sciences (WVE) Q2 2025 Earnings Call July 30, 2025 08:30 AM ET Speaker0Hello, and welcome to Wave Life Sciences' Second Quarter twenty twenty five Earnings Call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. I will now pass the call over to Kate Rausch, Vice President of Corporate Affairs and Investor Relations.Speak ...

业绩总结 - 2025年第二季度，Tyvaso DPI和雾化Tyvaso的产品收入为4.7亿美元，同比增长18%[21] - Remodulin的产品收入为1.35亿美元，同比下降9%[21] - Orenitram的产品收入为1.24亿美元，同比增长16%[21] - Unituxin的产品收入为5800万美元，同比增长13%[21] - 总收入为7.99亿美元，同比增长12%[21] - 过去12个月的运营现金流为14亿美元[22] - 现金、现金等价物和可市场投资总额为50亿美元[22] 用户数据 - 目前全球有10万名患者受到特发性肺纤维化影响，每年新增3万到4万例[58] - Tyvaso的全球收入同比增长18%，达到4.7亿美元，美国收入同比增长17%，达到4.55亿美元[147] - Orenitram的收入同比增长16%，达到1.24亿美元，连续第14个季度实现同比收入增长[151] - Remodulin的全球收入同比下降9%，达到1.35亿美元，美国收入同比下降7%，达到1.14亿美元[152] - Unituxin的全球收入同比增长13%，达到5800万美元，美国收入同比增长18%，达到5500万美元[158] 未来展望 - 预计未来收入将达到30亿美元、40亿美元、80亿美元和160亿美元的多个增长阶段[26] - TETON 2的预计时间表显示，2025年9月完成，2026年上半年完成TETON 1，2027年计划上市[85][86] - 预计TETON 1和TETON 2的数据分别在2026年上半年和2025年下半年发布[129] 新产品和新技术研发 - TPIP在PAH患者的Phase 2b研究中，6MWD（六分钟步行距离）活跃组与安慰剂组之间的差距超过3倍[95] - TPIP的市场推出预计在2029年至2030年之间[116] - TPIP在PH-ILD的Phase 2a研究中，未显示出统计学显著的6MWD变化[101] - TPIP的长期安全性尚未得到证明，目前仅有16周的安全性数据[114] 负面信息 - TPIP Phase 2b研究中，活跃组的患者中有10%停止治疗，而安慰剂组则为零[98] - TPIP的临床结果研究预计需要更长时间进行，可能会延迟市场批准[116] - TPIP在PH-ILD的研究中，活跃组的脱落率为10%，而对照组为零，显示出患者群体的不平衡[114] 其他新策略 - 公司已授权回购10亿美元的股票，截止日期为2026年3月31日[31] - Ralinepag在24个月的开放标签数据中，PVR减少52 dyn.s/cm，6MWD增加36米[137]

Q2 2025 EARNINGS CALL JULY 30, 2025 Anika. Restore Active Living. SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meanin ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 WVE-007, an IN ...

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for sub ...

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second ha ...

Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase 2a study is a mult ...

肿瘤相关成纤维细胞 （CAF） 是一类异质性细胞，通过细胞外基质 （ECM） 重塑、旁分泌信号转导和免 疫抑制来支持肿瘤生长和转移。CAF 通过直接抑制 CD8 + T 细胞或招募 髓源性抑制细胞 （MDSC） 来抑 制抗肿瘤免疫，从而限制了免疫检查点阻断 （ICB） 的疗效。 虽然癌症相关成纤维细胞 （CAF） 在支持癌症方面发挥着关键作用，但目前仍然缺乏靶向 CAF 的疗法。 2025 年 7 月 23 日，芝加哥大学的研究人员在国际顶尖学术期刊 Nature 上发表了题为： NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity 的研究论文。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 该研究揭示了 NNMT 通过 癌症相关成纤维细胞 （CAF） 招募 髓源性抑制细胞 （MDSC） 进入肿瘤，进 而促进免疫抑制性肿瘤微环境 （TME） 的形成。在此基础上，研究团队开发了 强效且特异性的 NNMT 抑 制剂 ，能够恢复抗肿瘤免疫。 在这项最新研究中，研究团队利用空间转录组学和单细胞 RNA 测序技术，探究了 烟 ...